Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

The new drug application is supported by 48-week data from the Phase III MK-8591A-051 and MK-8591A-052 trials, which showed ...

The FDA accepted Aldeyra's resubmitted NDA for reproxalap after previous rejections due to efficacy concerns, despite no ...

By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often ...

Potential NIH and FDA cuts could lower the number of new drugs that come to market in the next three decades, according to a ...

Pierre Fabre Pharmaceuticals, Inc. today announced the transfer of the Investigational New Drug Application for tabelecleucel ...

Aldeyra Therapeutics (NASDAQ:ALDX) announced on Thursday that the U.S. Food and Drug Administration (FDA) accepted for review ...

Johnson & Johnson (JNJ) said on Tuesday that it has submitted a supplemental new drug application to the U.S. Food and Drug ...

An FDA advisory panel will meet July 18 to consider a supplemental new drug application for the antipsychotic brexpiprazole, ...

A new report looks at hiring trends © 2025 American City Business Journals. All rights reserved. Use of and/or registration ...

Detailed price information for Eton Pharmaceutcials Inc (ETON-Q) from The Globe and Mail including charting and trades.

Johnson & Johnson (JNJ) gets FDA priority review for TAR-200 gains, a drug releasing system targeting bladder cancer. Read ...